Additionally, BCL6 peptide inhibitors like BTB binding domain motif (BBD) peptides, and retro-inverted BCL6 peptide inhibitor (RI-BPI) peptides can block co-repressor activity and have been shown in multiple studies to inhibit the growth of B cell lymphoma cell lines in vitro and resulting tumor growth in mouse models (46, 49). The gene discussed is BCL6; the disease is B-cell non-Hodgkin lymphoma.